Lyell Immunopharma (NASDAQ:LYEL) Trading Up 4.9%

Lyell Immunopharma, Inc. (NASDAQ:LYELGet Free Report)’s share price was up 4.9% during mid-day trading on Thursday . The company traded as high as $2.58 and last traded at $2.57. Approximately 233,721 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 963,725 shares. The stock had previously closed at $2.45.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright cut their target price on shares of Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, February 29th.

View Our Latest Research Report on Lyell Immunopharma

Lyell Immunopharma Stock Up 13.2 %

The firm has a 50-day simple moving average of $2.23 and a 200-day simple moving average of $1.98. The stock has a market cap of $764.84 million, a PE ratio of -3.24 and a beta of -0.56.

Lyell Immunopharma (NASDAQ:LYELGet Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $4.96 million. Lyell Immunopharma had a negative return on equity of 32.67% and a negative net margin of 180,486.14%. On average, research analysts expect that Lyell Immunopharma, Inc. will post -0.91 earnings per share for the current year.

Institutional Trading of Lyell Immunopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Advisor Group Holdings Inc. raised its holdings in shares of Lyell Immunopharma by 3,125.3% in the 4th quarter. Advisor Group Holdings Inc. now owns 7,902 shares of the company’s stock valued at $27,000 after acquiring an additional 7,657 shares in the last quarter. Royal Bank of Canada grew its position in Lyell Immunopharma by 76.1% in the first quarter. Royal Bank of Canada now owns 9,114 shares of the company’s stock worth $46,000 after acquiring an additional 3,940 shares in the last quarter. Metropolitan Life Insurance Co NY bought a new position in Lyell Immunopharma in the first quarter valued at $50,000. Mariner LLC purchased a new stake in Lyell Immunopharma during the fourth quarter valued at about $35,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Lyell Immunopharma in the 1st quarter worth about $52,000. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

(Get Free Report)

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

Recommended Stories

Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with's FREE daily email newsletter.